Utah Psychedelic-Assisted Therapy Clinical Study for Veterans

Enacted by chapter 196 of the 2026 general session, this is the newest veteran health provision in Utah and the only one of its kind in this catalog. It is recorded here so a veteran can understand what it is and, just as importantly, what it is not. What the statute directs. Section 26B-7-126, subsection 2: subject to appropriations and to gifts, grants and donations, "the Huntsman Mental Health Institute shall conduct a clinical study to research the safety and feasibility of psychedelic-assisted therapy for the treatment of treatment-resistant PTSD in eligible veterans." The Huntsman Mental Health Institute is defined in subsection 1 as "the mental health and substance use treatment institute within the University of Utah". Who is an eligible veteran. Subsection 1, paragraph (c): "'Eligible veteran' means a veteran who has treatment-resistant PTSD." Paragraph (k) defines treatment-resistant PTSD as "a clinical diagnosis of PTSD with documented inadequate response to one or more evidence-based treatments for PTSD." So two conditions: a clinical PTSD diagnosis, and documentation that at least one evidence-based treatment did not work well enough. Note that "veteran" carries the general Utah definition in section 68-3-12.5, and that nothing in the section requires the PTSD to be service-connected or rated by VA. What drugs are in scope. Paragraph (h) defines "psychedelic drug" as a controlled substance that is an investigational drug with a hallucinogenic effect on the central nervous system, "including: (i) 3,4-Methylenedioxymethamphetamine (MDMA); (ii) 5-methoxy-N,N-dimethyltryptamine; or (iii) Psilocybin." And what the therapy means. Paragraph (i): an intervention where a psychedelic drug is administered "in a controlled clinical setting" and "a qualified therapist delivers manualized, trauma-informed preparatory and integrative psychotherapy to the individual before and after administration of the psychedelic drug." The psychotherapy either side of the dose is part of the definition, not an optional extra. This is a study, and the statute is emphatic about the guardrails. Subsection 7 requires the institute, before beginning, to comply with state and federal regulation including by ensuring the study is conducted under an FDA investigational new drug application, maintaining a Drug Enforcement Administration Schedule I research registration and any required state controlled substance registration, and obtaining Institutional Review Board approval. It must also have a study protocol covering design, inclusion and exclusion criteria, objectives and endpoints, the visit schedule and follow-up assessments, informed consent procedures and participant safeguards, and data security and privacy protections; a drug administration plan covering the product, formulation, route, dosing, staffing, monitoring, discharge criteria and transportation after a session, and chain of custody and disposal of controlled substances; a safety monitoring and risk management plan covering medical and psychiatric screening, on-site emergency response, adverse event reporting timelines and "predefined rules for pausing or stopping the clinical study"; and a fidelity plan including a psychotherapy manual. The practical reading of all that: participation means enrolling in a regulated trial with screening, exclusion criteria, consent procedures and follow-up, not asking a clinician for a prescription. When it starts, and the condition on which everything turns. Subsection 2 makes the duty subject to subsections 4 and 5 and to "appropriations from the Legislature for this purpose and any gifts, grants, or donations". Subsection 3 lets the institute accept gifts, grants and donations of money to fund it. Subsection 4, paragraph (a): the institute "shall begin the clinical study no later than January 1, 2027, if the total amount of legislative appropriations and gifts, grants, or donations... reaches an amount that is equal to or exceeds an amount the Huntsman Mental Health Institute determines is sufficient to begin the clinical study." Subsection 5: if it does not begin by January 1, 2027 because the money is insufficient, the institute may keep accepting donations after that date, "shall begin the clinical study when the total amount... reaches an amount... sufficient to begin", and may use money received or appropriated after that date to continue funding it. So there is a target date and a funding condition, and the institute itself judges what is sufficient. A veteran interested in participating should ask the institute whether the study has opened rather than assume the January 2027 date. An outer limit on the money. Subsection 6: the institute "shall return to a donor any unused gifts, grants, or donations... on or before July 1, 2032." That is effectively a six-year horizon on the funding, though not a repeal of the section. What this is not, and it matters. It is not a treatment programme, not a state-funded therapy benefit, and not a route to a psychedelic prescription. The drugs are investigational and Schedule I; administration happens only inside a study under an FDA investigational new drug application. Nothing in the section creates an entitlement to participate, and the protocol's inclusion and exclusion criteria will decide who does. Where to look for care that exists today. VA provides evidence-based PTSD treatment including prolonged exposure and cognitive processing therapy, and Utah has Vet Centers in Murray, South Ogden, Orem and St. George offering confidential counselling at no cost, including for military sexual trauma, plus the George E. Wahlen VA Medical Center in Salt Lake City and seven community-based outpatient clinics. Section 71A-1-201, subsection 4, paragraph (o) makes mental wellness and counselling part of the Department of Veterans and Military Affairs' service mandate. The Veterans Crisis Line is reachable by dialling 988 then pressing 1. A neighbouring Utah provision a veteran with PTSD should know about: section 26B-4-203 defines the qualifying conditions for Utah's medical cannabis programme, and PTSD is among them. That is an existing, operating programme rather than a study.